查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012371

3D列印藥品市場：2026-2032年全球市場預測（依3D列印技術、劑型、藥物釋放、治療領域及最終用戶分類）

3D Printed Drugs Market by 3D Printing Technology, Dosage Form, Drug Release, Therapeutic Area, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，3D 列印藥品市場價值將達到 2.0289 億美元，到 2026 年將成長到 2.3128 億美元，到 2032 年將達到 5.3885 億美元，年複合成長率為 14.97%。

主要市場統計數據
基準年 2025 2.0289億美元
預計年份：2026年 2.3128億美元
預測年份 2032 5.3885億美元
複合年成長率 (%) 14.97%

透過詳細介紹技術創新、產業發展和策略機遇，為 3D 列印藥物奠定基礎。

3D列印技術正在革新製藥產業，以前所未有的方式提升藥物研發和生產的客製化程度、精準度和速度。這項技術突破了傳統生產的局限，能夠按需生產複雜劑型，並為每位患者提供最佳的劑量、形狀和釋放曲線。這種模式轉移得益於硬體設計的進步、新型可列印材料的出現以及與傳統品管和法律規範無縫銜接的先進數位化工作流程。

揭示由 3D 列印技術、不斷變化的法規和協作生態系統的動態所驅動的製藥製造領域的變革性變化。

隨著3D列印技術從概念驗證（PoC）階段邁向商業性化應用，製藥業正經歷一場根本性的變革。首先，從大量生產向數位化生產的轉變正在重塑供應鏈的結構。本地化和按需生產使製造商能夠透過精準的、針對特定患者的劑量設置，最大限度地縮短庫存週期，降低物流複雜性並減少廢棄物。

評估 2025 年美國關稅對供應鏈韌性、成本結構和策略採購決策的累積影響。

美國2025年實施的新關稅預計將對全球3D列印醫藥供應鏈產生重大影響。高額進口關稅可能針對從海外採購的原料和特殊聚合物，直接影響硬體製造商和醫藥創新者的成本結構。為此，各企業正在評估替代籌資策略，並考慮將關鍵零件重新引入國內市場，以維持業務永續營運。

對 3D 列印藥物市場的市場動態進行關鍵細分洞察，涵蓋技術方法、劑型、釋放曲線、治療領域和最終用戶。

3D列印藥物市場的特點是技術方法多種多樣，以滿足不同的臨床需求和生產規模。積層製造流程涵蓋噴嘴式和顆粒式熔融沈積成型（FDM）、噴墨列印和選擇性雷射燒結（SLS），以及高解析度立體光刻技術平台。每種方法在解析度、材料相容性和生產效率方面各有側重，使開發人員能夠選擇最適合其特定劑型設計的製程。

戰略區域分析，重點關注美洲、歐洲、中東、非洲和亞太地區的成長要素和市場特徵。

區域趨勢在塑造3D列印醫療技術的應用和創新軌跡方面發揮著至關重要的作用。在美洲，對數位基礎設施的大規模投資和配套的法規結構正在加速試驗計畫和商業化進程。主要企業和研究機構正緊密合作，將開創性的配方轉化為面向患者的產品。

對透過創新、合作和策略經營模式推動 3D 列印製藥產業的主要企業進行詳細分析。

3D列印製藥產業的領導者正透過投資專有硬體平台、新型可列印聚合物和整合數位生態系統來脫穎而出。專注於高解析度立體光刻技術的公司正與材料科學公司建立策略合作夥伴關係，以開發符合嚴格監管標準的生物相容性樹脂。其他公司則致力於透過與聚合物製造商合作來擴大熔融沈積成型（FDM）技術的規模，並拓展其藥物浸漬絲材的產品線。

為行業領導者提供實用指導，以推動 3D 列印藥物的採用，並克服監管、營運和夥伴關係的挑戰。

尋求利用3D列印製藥技術的產業領導者必須採取多管齊下的策略，協調創新、監管合規和卓越營運。一個關鍵步驟是投資於模組化硬體系統，以適應未來材料和設計的進步，從而確保長期的柔軟性。同時，各機構應與材料科學專家建立夥伴關係，共同開發針對特定治療應用最佳化的生物相容性聚合物。

一套全面的調查方法，詳細說明了構成市場洞察基礎的資料來源、分析架構和品質保證措施。

本報告的研究結果是基於嚴謹的調查方法，整合了第一手資料和二手資料。第一手資料包括對高階主管、研發負責人、監管專家和終端用戶代表進行深度訪談，以獲取關於技術採納、市場動態和營運挑戰的第一手觀點。這些質性見解輔以針對不同治療領域關鍵採納計畫的詳細案例研究。

整合關鍵研究成果，展望 3D 列印藥物的未來發展軌跡和產業演變。

3D列印藥物的未來發展趨勢是技術創新、法規結構演進和策略合作的融合，這些因素共同預示著個人化醫療新時代的到來。積層製造技術已展現出其解決長期存在的挑戰（例如製劑設計、供應鏈柔軟性和患者依從性）的能力，同時也開啟了新的治療可能性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：3D列印製藥市場：依3D列印技術分類

  • 積層製造（FDM）
    • 噴嘴類型
    • 顆粒法
  • 噴墨列印
  • 選擇性雷射燒結
  • 立體光刻技術

第9章：3D列印藥物市場：依劑型分類

  • 膠囊
  • 奈米顆粒
  • 藥片

第10章：3D列印藥物市場：依藥物釋放方式分類

  • 緩釋
  • 延遲釋放
  • 立即發布

第11章：3D列印藥品市場：依治療領域分類

  • 循環系統
  • 牙科
  • 神經病學
  • 腫瘤學

第12章：3D列印製藥市場：依最終用戶分類

  • 合約研究機構
  • 醫院和診所
  • 製藥公司
  • 研究機構

第13章：3D列印藥品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：3D列印藥品市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 3D列印藥品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：3D列印製藥市場

第17章 中國：3D列印製藥市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 3D Systems, Inc.
  • Anatomics Pty Ltd.
  • Aprecia Pharmaceuticals, LLC
  • Curify Ltd
  • Cyfuse Biomedical KK
  • FabRx Ltd.
  • GlaxoSmithKline Plc
  • Laxxon Medical Corp.
  • MB Therapeutics
  • Merck KGaA
  • Proto Labs Inc.
  • Renishaw PLC
  • Siemens AG
  • Triastek, Inc.
  • Yissum
Product Code: MRR-431C35F6C179

The 3D Printed Drugs Market was valued at USD 202.89 million in 2025 and is projected to grow to USD 231.28 million in 2026, with a CAGR of 14.97%, reaching USD 538.85 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 202.89 million
Estimated Year [2026] USD 231.28 million
Forecast Year [2032] USD 538.85 million
CAGR (%) 14.97%

Setting the Stage for 3D Printed Pharmaceuticals with an In-Depth Introduction to Technological Innovations, Industry Evolution, and Strategic Opportunities

3D printing is revolutionizing the pharmaceutical industry by enabling unprecedented levels of customization, precision, and speed in drug development and manufacturing. The technology transcends traditional production constraints by allowing on-demand fabrication of complex dosage forms with patient-specific dosing, shapes, and release profiles. This paradigm shift is fueled by advances in hardware design, novel printable materials, and sophisticated digital workflows that integrate seamlessly with conventional quality control and regulatory frameworks.

As stakeholders across the entire pharmaceutical value chain-from research laboratories to clinical settings-embrace additive manufacturing, the implications extend beyond novel product formats. Development timelines are being compressed through rapid prototyping, formulation screening, and iterative design. Manufacturing footprints are evolving to support decentralized production models that bring drug fabrication closer to the point of care. Meanwhile, emerging regulatory pathways are adapting to this disruptive technology, fostering an environment where safety and innovation coalesce.

This executive summary provides a concise yet comprehensive introduction to the drivers, opportunities, and challenges shaping the 3D printed drugs market. It captures the technological underpinnings, regulatory catalysts, and commercial imperatives that are steering transformative change. Decision-makers will find an authoritative overview designed to inform strategic planning, investment decisions, and collaborative initiatives in the pursuit of next-generation pharmaceutical solutions.

Unveiling Transformative Shifts in Pharmaceutical Manufacturing Driven by 3D Printing Technologies, Regulatory Evolutions, and Collaborative Ecosystem Dynamics

The pharmaceutical landscape is undergoing fundamental shifts as 3D printing moves from proof-of-concept to commercial viability. First, the transition from batch manufacturing to digital production is redefining supply chain architectures. By enabling localized and on-demand fabrication, manufacturers can minimize inventory lifecycles, reduce logistics complexities, and mitigate wastage through precise dosing tailored to individual patients.

Second, regulatory agencies have begun to establish frameworks that embrace additive processes. The introduction of guidelines addressing digital file integrity, material characterization, and process validation is streamlining approval pathways. This alignment between industry and regulators cultivates a fertile environment for innovation while safeguarding quality and patient safety.

Third, strategic collaborations among technology providers, pharmaceutical companies, and contract research organizations are accelerating translation from laboratory to clinic. Shared investments in research platforms, standardization efforts, and joint development agreements are unlocking synergies that amplify technological capabilities and market readiness.

Together, these dynamics are reshaping the pharmacological development continuum. Innovations in materials science, hardware engineering, and digital design converge with progressive regulatory approaches to produce a manufacturing paradigm that balances customization with scalability. As these transformative shifts unfold, stakeholders are well positioned to capitalize on the next frontier of personalized medicine.

Assessing the Cumulative Impact of United States Tariffs in 2025 on the Supply Chain Resilience, Cost Structures, and Strategic Sourcing Decisions

The imposition of new United States tariffs in 2025 is poised to exert significant influence on the global 3D printed drug supply chain. Raw materials and specialized polymers sourced from overseas may incur elevated import duties, directly impacting the cost structure for hardware manufacturers and pharmaceutical innovators alike. In response, organizations are evaluating alternative procurement strategies and considering reshoring critical components to maintain operational resilience.

Moreover, the increased financial burden is prompting stakeholders to revisit long-term sourcing partnerships. Collaborative relationships with domestic suppliers are being strengthened to hedge against volatility, while cross-border alliances are renegotiated to accommodate the revised tariff regime. Such adaptations are essential to preserving margins without compromising the robustness of material supply pipelines.

In parallel, the cost implications of tariffs are accelerating investments in process optimization. Manufacturers are exploring consolidation of material usage, recycling initiatives, and novel material formulations that deliver comparable performance at lower expense. Digital optimization tools, including predictive analytics and process monitoring, are being harnessed to maximize yield and minimize waste.

While the tariff landscape introduces new complexities, it also serves as a catalyst for strategic supply chain innovation. By proactively addressing the implications of policy shifts, industry players can fortify their resilience and secure a competitive edge in the evolving 3D printed drugs market.

Key Segmentation Insights into 3D Printed Drug Market Dynamics Spanning Technology Approaches, Dosage Forms, Release Profiles, Therapeutic Areas, and End Users

The 3D printed drug market is characterized by a diverse array of technological approaches that cater to distinct clinical requirements and manufacturing scales. Additive processes range from nozzle-based and pellet-based fused deposition modeling to inkjet and selective laser sintering, culminating in high-resolution stereolithography platforms. Each modality offers its own balance of resolution, material compatibility, and throughput, enabling developers to select the optimal method for specific dosage designs.

Beyond hardware, the spectrum of dosage forms has expanded to include traditional tablets, encapsulated solids, and cutting-edge nanoparticle constructs. These formats are engineered to enhance patient compliance, bioavailability, and therapeutic targeting. Meanwhile, the ability to tailor drug release profiles-controlled, delayed, or immediate-empowers formulators to optimize pharmacokinetics while reducing side effects.

Therapeutic applications traverse multiple medical disciplines. Cardiovascular, dental, neurology, and oncology treatments have all benefited from precision-fabricated dosage forms that address unique absorption and delivery challenges. End users such as contract research organizations, hospitals and clinics, pharmaceutical companies, and academic research institutes are collaborating to pioneer clinical validation and scale production.

By integrating technology, form factor, release mechanism, therapeutic focus, and end-user requirements, the market presents a nuanced landscape ripe for segmentation-driven growth. Companies that align their capabilities with these distinct vectors can unlock tailored solutions and capture specialized niches within the broader 3D printed drugs ecosystem.

Strategic Regional Analysis Highlighting Growth Drivers and Market Characteristics across the Americas, Europe Middle East and Africa, and Asia Pacific

Regional dynamics play a critical role in shaping the adoption and innovation trajectory of 3D printed pharmaceuticals. In the Americas, extensive investment in digital infrastructure and supportive regulatory frameworks have accelerated pilot programs and commercial launches. Leading pharmaceutical companies and research institutions collaborate closely to translate pioneering formulations into patient-ready products.

The Europe, Middle East and Africa region exhibits a complex tapestry of regulatory environments and healthcare priorities. Progressive policies in Western Europe are enabling clinical trials and early market entry, while emerging markets in the Middle East and Africa are gradually building capacity through public-private partnerships and targeted innovation incentives. This diversity fosters a dynamic landscape where regional centers of excellence co-exist with opportunities for market expansion.

In the Asia-Pacific region, rapid industrial growth and strong governmental backing for advanced manufacturing have positioned several nations at the forefront of additive pharmaceutical development. Significant R&D expenditure, coupled with a substantial generic drug manufacturing base, has catalyzed both homegrown and collaborative ventures. Stakeholders in this region are leveraging economies of scale to reduce costs and drive large-scale adoption of 3D printing technologies in clinical settings.

These regional nuances underscore the importance of tailored strategies that reflect local regulatory requirements, technological readiness, and healthcare priorities. Companies that adapt their market approaches accordingly are poised to capture growth in these geographically diverse markets.

In-Depth Examination of Key Companies Shaping the 3D Printed Pharmaceuticals Sector through Innovation, Collaborations, and Strategic Business Models

Industry leaders across the 3D printed pharmaceuticals space are distinguished by their investments in proprietary hardware platforms, novel printable polymers, and integrated digital ecosystems. Companies specializing in high-resolution stereolithography have established strategic collaborations with material science firms to develop biocompatible resins that meet stringent regulatory standards. Others have focused on scaling fused deposition modeling through partnerships with polymer manufacturers to expand the library of drug-loaded filaments.

Collaborative alliances between pharmaceutical giants and additive manufacturing pioneers have yielded joint development agreements that accelerate clinical validation pathways. These partnerships combine formulation expertise with cutting-edge printing technologies, facilitating the rapid translation of research-grade prototypes into scalable production lines. Licensing deals and co-development contracts have become pivotal mechanisms for sharing risk and maximizing market reach.

In addition, contract research organizations have carved out specialized service offerings that encompass formulation screening, process development, and regulatory support for 3D printed dosage forms. By embedding end-to-end capabilities, they serve as essential enablers for companies seeking to outsource critical development milestones. This convergence of capabilities is shaping a competitive landscape where collaboration, intellectual property differentiation, and service depth determine market leadership.

As the ecosystem continues to evolve, companies that balance technological innovation with robust business models and strategic partnerships will emerge as frontrunners in the 3D printed drugs domain.

Actionable Guidance for Industry Leaders to Drive 3D Printed Drug Adoption and Navigate Regulatory, Operational, and Partnership Challenges

Industry leaders seeking to capitalize on 3D printed drug technologies must adopt a multi-faceted strategy that aligns innovation with regulatory preparedness and operational excellence. A foundational step is to invest in modular hardware systems that can accommodate future material and design advancements, thereby safeguarding long-term flexibility. Concurrently, organizations should cultivate partnerships with material science experts to co-develop biocompatible polymers optimized for specific therapeutic applications.

Engagement with regulatory authorities is equally critical. Proactive dialogue and participation in standardization initiatives enable companies to influence emerging guidelines and anticipate compliance requirements. Embedding quality-by-design principles into digital workflows will streamline approval processes and reinforce product reliability.

Operational resilience demands a reassessment of supply chain risk profiles. Firms should diversify raw material sources, explore near-shoring opportunities, and implement digital tools for real-time monitoring of material integrity and production performance. Incorporating data analytics and predictive maintenance into manufacturing environments will further enhance continuity and cost efficiency.

Lastly, cultivating an ecosystem of academic collaborators, contract research organizations, and clinical partners will accelerate translational efforts. By orchestrating cross-disciplinary innovation networks, industry players can catalyze the adoption of 3D printed pharmaceuticals and drive sustainable growth in this transformative market.

Comprehensive Research Methodology Detailing Data Sources, Analytical Frameworks, and Quality Assurance Measures Underpinning the Market Insights

The findings presented in this report are grounded in a rigorous research methodology that integrates both primary and secondary data sources. Primary research involved in-depth interviews with senior executives, R&D heads, regulatory specialists, and end-user representatives to capture firsthand perspectives on technology adoption, market dynamics, and operational challenges. These qualitative insights were supplemented by detailed case studies of leading implementation projects across diverse therapeutic areas.

Secondary research encompassed analysis of regulatory filings, patent databases, industry white papers, and technical journals to map the evolution of additive manufacturing in pharmaceuticals. Publicly available information on collaborative agreements, clinical trial registries, and company disclosures provided additional context on strategic trends and competitive positioning.

Data triangulation techniques were employed to cross-verify insights, ensuring consistency and robustness of conclusions. Analytical frameworks focused on segmentation by technology, dosage form, release mechanism, therapeutic area, end user, and region. This multi-dimensional approach enabled the identification of nuanced growth drivers, barriers to entry, and emerging opportunities.

Quality assurance measures included peer reviews by subject matter experts and validation of key data points against multiple independent sources. This comprehensive methodology underpins the credibility of the report's insights, equipping decision-makers with an authoritative resource on the 3D printed drugs market.

Synthesizing Core Findings and Forward-Looking Perspectives on the Future Trajectory of 3D Printed Pharmaceuticals and Industry Evolution

The trajectory of 3D printed pharmaceuticals is characterized by converging technological innovation, evolving regulatory frameworks, and strategic collaborations that collectively promise a new era of personalized medicine. Additive manufacturing has demonstrated its capacity to address longstanding challenges in drug formulation, supply chain flexibility, and patient compliance, while also stimulating novel therapeutic possibilities.

Despite the transformative potential, stakeholders must navigate policy changes, cost considerations, and material development hurdles. The 2025 tariff environment underscores the importance of supply chain agility and the need for strategic sourcing partnerships. Moreover, the success of market adoption hinges on the harmonization of quality standards and regulatory alignment.

Looking ahead, continued investment in R&D, expansion of printable material libraries, and refinement of digital design tools will drive the next phase of growth. Regions that cultivate supportive ecosystems-combining regulatory clarity, academic-industry collaboration, and investment incentives-will emerge as global innovation hubs.

Ultimately, the maturation of the 3D printed drugs market will be shaped by the ability of industry leaders to translate technological breakthroughs into scalable, patient-centric solutions. With deliberate strategy, collaborative networks, and a proactive regulatory mindset, the promise of tailored, on-demand pharmaceuticals can be fully realized.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. 3D Printed Drugs Market, by 3D Printing Technology

  • 8.1. Fused Deposition Modeling
    • 8.1.1. Nozzle-Based
    • 8.1.2. Pellet-Based
  • 8.2. Inkjet Printing
  • 8.3. Selective Laser Sintering
  • 8.4. Stereolithography

9. 3D Printed Drugs Market, by Dosage Form

  • 9.1. Capsules
  • 9.2. Nanoparticles
  • 9.3. Tablets

10. 3D Printed Drugs Market, by Drug Release

  • 10.1. Controlled Release
  • 10.2. Delayed Release
  • 10.3. Immediate Release

11. 3D Printed Drugs Market, by Therapeutic Area

  • 11.1. Cardiovascular
  • 11.2. Dental
  • 11.3. Neurology
  • 11.4. Oncology

12. 3D Printed Drugs Market, by End User

  • 12.1. Contract Research Organizations
  • 12.2. Hospitals & Clinics
  • 12.3. Pharmaceutical Companies
  • 12.4. Research Institutes

13. 3D Printed Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. 3D Printed Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. 3D Printed Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States 3D Printed Drugs Market

17. China 3D Printed Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. 3D Systems, Inc.
  • 18.6. Anatomics Pty Ltd.
  • 18.7. Aprecia Pharmaceuticals, LLC
  • 18.8. Curify Ltd
  • 18.9. Cyfuse Biomedical K.K.
  • 18.10. FabRx Ltd.
  • 18.11. GlaxoSmithKline Plc
  • 18.12. Laxxon Medical Corp.
  • 18.13. MB Therapeutics
  • 18.14. Merck KGaA
  • 18.15. Proto Labs Inc.
  • 18.16. Renishaw PLC
  • 18.17. Siemens AG
  • 18.18. Triastek, Inc.
  • 18.19. Yissum

LIST OF FIGURES

  • FIGURE 1. GLOBAL 3D PRINTED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL 3D PRINTED DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL 3D PRINTED DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA 3D PRINTED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL 3D PRINTED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NOZZLE-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NOZZLE-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NOZZLE-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PELLET-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PELLET-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PELLET-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY INKJET PRINTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY INKJET PRINTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY INKJET PRINTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY SELECTIVE LASER SINTERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY SELECTIVE LASER SINTERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY SELECTIVE LASER SINTERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY STEREOLITHOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY STEREOLITHOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY STEREOLITHOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTROLLED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTROLLED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DELAYED RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DELAYED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DELAYED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DENTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DENTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY DENTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 136. GCC 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 137. GCC 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 139. GCC 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. G7 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 157. G7 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. G7 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 160. G7 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. NATO 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 164. NATO 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 165. NATO 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 167. NATO 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL 3D PRINTED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA 3D PRINTED DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA 3D PRINTED DRUGS MARKET SIZE, BY 3D PRINTING TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA 3D PRINTED DRUGS MARKET SIZE, BY FUSED DEPOSITION MODELING, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA 3D PRINTED DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA 3D PRINTED DRUGS MARKET SIZE, BY DRUG RELEASE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA 3D PRINTED DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA 3D PRINTED DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)